Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: A meta-analysis by Li, Z. et al.
© Translational lung cancer research. All rights reserved.   Transl Lung Cancer Res 2019;8(6):775-786 | http://dx.doi.org/10.21037/tlcr.2019.10.11
Original Article
Sleeve lobectomy compared with pneumonectomy for operable 
centrally located non-small cell lung cancer: a meta-analysis
Zhengjun Li1, Wei Chen2, Mozhu Xia3, Hongxu Liu2, Yongyu Liu1, Ilhan Inci4, Fabio Davoli5, 
Ryuichi Waseda6, Pier Luigi Filosso7, Abby White8
1Department of Thoracic Surgery, Shenyang Chest Hospital, Shenyang 110044, China; 2Department of Thoracic Surgery, Cancer Hospital of China 
Medical University/Liaoning Cancer Hospital, Shenyang 110042, China; 3Department of Thoracic Surgery, The First Affiliated Hospital, China 
Medical University, Shenyang 110001, China; 4Department of Thoracic Surgery, University Hospital, University of Zurich, Zurich, Switzerland; 
5Department of Thoracic Surgery, AUSL Romagna, S. Maria delle Croci Teaching Hospital, Ravenna, Italy; 6Department of General Thoracic, 
Breast, and Pediatric Surgery, Fukuoka University, Fukuoka, Japan; 7Unit of Thoracic Surgery, Department of Surgical Sciences, University of 
Torino, Torino, Italy; 8Division of Thoracic Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA
Contributions: (I) Conception and design: Z Li; (II) Administrative support: H Liu, Y Liu; (III) Provision of study materials or patients: Z Li, W Chen, 
M Xia; (IV) Collection and assembly of data: Z Li, W Chen, M Xia; (V) Data analysis and interpretation: Z Li, W Chen, M Xia; (VI) Manuscript 
writing: All authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Hongxu Liu. Department of Thoracic Surgery, Cancer Hospital of China Medical University/Liaoning Cancer Hospital, Shenyang 
110042, China. Email: hongxuliu@qq.com; Yongyu Liu. Department of Thoracic Surgery, Shenyang Chest Hospital, Shenyang 110044, China. 
Email: freeman-2006@163.com.
Background: The purpose of this meta-analysis was to evaluate evidence comparing sleeve lobectomy (SL) 
and pneumonectomy (PN) in the treatment of non-small cell lung cancer (NSCLC).
Methods: The English literature search was undertaken in January 2018 and included studies dating back 
to 1996. Comparative studies were identified, evaluating survival, local recurrence, and distant recurrence 
rates, operative mortality, 30-day mortality, as well as complications. A pooled odds ratio (OR) and 95% 
confidence intervals (95% CI) were calculated with either the random or fixed-effect model.
Results: A total of 27 studies were identified, with publication dates between 1996 and 2018. These  
27 studies included a total of 14,194 patients: 4,145 treated with SL and 10,049 treated with PN. The 
overall survival was significantly higher in the SL group compared to the PN one at 1, 3, 5 years. In patients 
with N0 and N1 disease, 5-year survival rates following SL exceeded those following PN. There was no 
statistically significant difference in the 3-, 5-year overall survival of N2 patients, according to the extent 
of surgery. The PN group had a higher rate of operative mortality, 30-day mortality and distant recurrence 
incidence. However, no statistical difference in complications and local recurrence between SL and PN were 
observed.
Conclusions: SL is an effective treatment option for hilar NSCLC with improved long-term survival 
compared to PN, with no increase of recurrence rate or postoperative complications. Furthermore, N2 
disease is an important factor related to survival, and lymph node downstaging is a favorable prognostic 
factor.
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Introduction
Lung cancer is the most common cancer in the world. 
Surgery remains the standard of care for localized 
disease, even when the location or extent of the disease 
needs pneumonectomy (PN) to be radically treated. The 
treatment of centrally located tumors has always been 
controversial. Bronchial sleeve resection was introduced 
in 1947 (1) by Thomas as a means to preserve functional 
lung parenchyma in patients with compromised pulmonary 
function; the first sleeve lobectomy (SL) report dates 
1954 (1,2) by Allison and Coll. SL was considered as an 
alternative to PN since then several institutions worldwide 
(2-7) proposed SL in alternative to PN. Recent studies (8,9) 
have shown that SL compared to PN can improve lung 
cancer patients’ quality of life also prolonging long-term 
survival. Most surgeons agree that SL has to be performed 
with technical precision in order to accomplish surgery 
complete tumor resection without increasing complications. 
Some recent studies suggested that sleeve resection 
should be used routinely in the management of patients 
with anatomically appropriate hilar tumors, regardless of 
preoperative lung function (10-13). One criticism to SL 
over PN is their potential risk for local recurrence. These 
reports suggest that local recurrence following SL was 
comparable, and long-term survival was similar to or better 
than after PN. Unfortunately, most of the reports show that 
tumor’ TNM stage distribution is very different between 
the two surgical approaches, and comparisons of the survival 
and local recurrence rates of comparison for the 2 different 
approaches over an appropriate stage stratification is not 
easy to perform.
The primary purpose of our research was to compare SL 
and PN’s outcome, focusing on (I) survival rates, (II) local 
and distant recurrence rates, (III) operative mortality, (IV) 
30-day mortality, and (V) type and rate of complications 
of these procedures, as well as to evaluate whether SL can 
be accepted as a favorable alternative procedure to PN for 
patients with non-small cell lung cancer (NSCLC).
Methods
Study selection
Electronic searches were performed of the MEDLINE, 
EMBASE databases and Cochrane Controlled Trial Register 
(CENTRAL) until January 2018. We use the following 
Mesh search headings to search: (sleeve lobectomy), 
(pneumonectomy), (centrally located lung cancer or lung 
carcinoma), (comparative study) and [randomized controlled 
trials (RCTs)] in English literature (Figure 1).
Data extraction and quality assessment
Three independent researchers followed the standard 
procedures for data extraction. The recorded data included: 
(I) the number of patients, (II) the 1-, 3-, 5-year overall 
survival, (III) the local and distant recurrence rates, (IV) the 
operative mortality, (V) the 30-day mortality, and (VI) the 
complications rates. The quality of all selected documents 
was ranked following the score of the non-randomized 
controlled clinical trial quality evaluation standard.
Study selection criteria
Inclusion criteria for this study were as follows: (I) 
absence of extrapulmonary metastasis; (II) lung function 
was appropriate for PN; (III) no prior or concurrent 
other neoplasms; (IV) the patients should be suitable for 
treatment with either SL or PN, and (V) they should have 
similar baseline demographics.
Exclusion criteria
The following publication criteria were excluded: abstracts, 
letters, editorials and expert opinions, reviews without 
original data, case reports and studies lacking control 
groups. Studies evaluating unresectable lung cancer or 
recurrence after lobectomy and those without reported 
outcomes of interest were excluded.
Surgical technique
The sleeve resection includes the resection of one lobe 
and the end-to-end bronchial anastomosis. The procedure 
for SL is the same as for standard lobectomy until the 
bronchus is isolated. The bronchus needs a single sharp 
incision divides, and the incision should avoid ragged edges. 
It should be noted that beyond the proposed line of the 
transaction, it is taken not to revascularize the bronchus. 
Several anastomosis techniques are described, mainly 
depending on the surgeon’s expertise and preference; 
even if any of them have to respect the basic surgical and 
oncological principles: (I) achieve tumor-free bronchial 
margins at the frozen section; (II) perform a tension-free 
anastomosis; (III) try to avoid bronchial mismatch and (IV) 
proceed with an en-bloc resection.
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The anastomosis could be done mainly in four different 
ways: (I) a running suture for the membranous part and 
single stitches for the cartilage (knots are tied outwards); (II) 
double continuous suture; (III) a single continuous suture 
for the whole anastomosis; (IV) fully interrupted sutures.
No difference in definitive outcome is observed by the 
different suture techniques.
Before proceeding to the bronchial anastomosis, a 
pathological frozen section confirmation of neoplastic 
cells absence in the proximal margin is required. At the 
end of the suture, the air leakage check is performed by 
submerging the lung in saline solution and re-ventilating it. 
If necessary, intra-operative fiberoptic bronchoscopy could 
be performed to examine the anastomosis directly. Usually, 
the bronchial anastomosis and the vascular structures are 
separated by vital pedicled pleura and pericardial fat, to 
prevent possible fistula. Additionally, a sleeve resection 
of more than 1 lobe with atypical bronchial resection and 
reconstruction was terminated as an extended SL by Okada 
et al. The extended procedure could be more complicated 
than the standard SL, and was classified as Okada type 
A–D based on the extent of resection and location of 
anastomose. Generally, lymph-node resection, according 
to the international guidelines (14) is performed before 
completing the bronchial anastomosis.
Statistical analysis
Statistical analysis was performed using the software 
package RevMan 5.1.0. Odds ratio (OR) or mean difference 
with 95% confidence intervals (95% CI) were calculated 
for dichotomous outcomes and continuous outcomes 
respectively. A random-effects and fixed-effect models 
were done using ‘intention-to-treat’ analysis. If the results 
were not different between the two models, the random-
effects model was reported, as this model was used for 
indirect comparisons. If results differed between the two 
models, both results were reported. Heterogeneity was 
explored by χ2 and I2. I2<25% and I2>50% reflect small 
and large inconsistency, respectively. If P>0.10, these 
studies were deemed to exhibit homogeneity and a fixed-
effect analysis model was used. When P<0.10 and I2<50%, 
these studies were considered to exhibit heterogeneity, 
but the heterogeneity could be accepted, and a fixed-effect 
analysis model was used too. When P<0.10 and I2>50%, the 
heterogeneity was too high to be accepted, and a random-
effect analysis model was used. A P value of <0.05 was 
considered significant.
References identified through 
electronic searches of databases
n=5,417
References excluded   n=181
Comments/reviews   n=69
Out of scope   n=112
References excluded   n=21
Incomplete information  n=6
Incomparable baseline of patients  n=15
References retrieved for more 
detailed evaluation
n=229
Potentially Prospective Studies to 
be included
n=48
References included in  
meta-analysis
n=27
References excluded   n=5,188
Duplicates irrelevant by reading  n=2,347
Titles and Abstracts   n=2,841
Figure 1 Identification of studies for inclusion.
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Subgroup analysis
A subgroup analysis was performed by including patients 
with pathological N0, N1 and N2 diseases.
Publication bias
We used funnel plots model to check for bias. Asymmetry 
in the funnel plot of trial size against treatment effect was 
used to assess the risk of bias.
Results
Description of studies
After screening (Figure 1), 27 studies were included. Of 
14,194 patients in these 27 studies, 4,145 were allocated 
to the SL group, whereas 10,049 to the PN group. Patient 
characteristics and evaluation index are shown in Table 1. 
Selected articles were ranked 7–8 on a quality-indicator 
scale by Newcastle-Ottawa scale (NOS). Results of the 
meta-analysis are summarized in Table 2.
Operative mortality (operating room and the perioperative 
period after surgery)
The meta-analysis {13 trials reported this data include 
22 [839] and 130 [2,064] patients in SL and PN} showed 
operative mortality in the PN group was significantly higher 
than in the SL group (6.30% vs. 2.62%) (OR: 0.40; 95% 
CI: 0.25–0.63; P<0.0001), with no evidence of significant 
heterogeneity.
30-day mortality
Twelve trials reported data {include 89 [3,195] and 463 [7,890] 
patients in SL and PN} on 30-day mortality and showed that 
there was statistical difference between SL and PN relative 
to 30-day mortality (2.78% vs. 5.86%) (OR: 0.55; 95% CI: 
0.32–0.96; P=0.04), with specific heterogeneity.
Complications
Concerning to perioperative complications, the meta-
analysis (15 trials reported this data) showed that there was 
no statistically significant difference between the SL and the 
PN groups (OR: 1.07; 95% CI: 0.87–1.31; P=0.55), with 
specific heterogeneity.
Local recurrence rates
Fifteen trials reported data on local recurrence. There was 
no statistically significant difference between the SL and the 
PN groups (OR: 1.09; 95% CI: 0.72–1.64; P=0.69), with 
specific heterogeneity.
Distant recurrence rates
Nine trials reported data on distant recurrence rates and 
demonstrated a higher risk of distant recurrence with PN 
compared to SL (OR: 0.61; 95% CI: 0.45–0.82; P=0.001), 
with no evidence of significant heterogeneity (Figure 2).
Overall survival rates
One-year survival rates: the meta-analysis (8 trials reported 
this data) showed that the group of SL experienced a 
significantly higher survival rate compared to PN (OR: 
1.53; 95% CI: 1.31–1.80; P<0.00001), with no evidence of 
significant heterogeneity.
Three-year survival rates: the meta-analysis (11 trials 
reported this data) showed that survival in PN group was 
significantly lower compared to SL (OR: 1.78; 95% CI: 
1.47–2.17; P<0.00001), with specific heterogeneity (Figure 3).
Five-year survival rates: the meta-analysis (20 trials 
reported this data) showed that survival in PN group as 
significantly lower compared to SL one (OR: 1.96; 95% CI: 
1.70–2.27; P<0.00001), with specific heterogeneity (Figure 4).
Comparison of overall survival rates between the two 
groups in N0 and N1, N2 (pathological) patients
When survival was evaluated according to the lymph 
node involvement and the type of resection, the results of 
5 trials demonstrated improved 5-year overall survival rates 
for patients with N0–N1 disease who underwent SL as 
compared to PN (OR: 2.14; 95% CI: 1.66–2.78; P<0.00001), 
with specific heterogeneity (Figure 5). In patients with N2 
disease, there was no statistically significant difference in 3- 
or 5-year overall survival concerning the type of resection 
(OR: 1.12; 95% CI: 0.47–2.68; P=0.79; OR: 1.27; 95% CI: 
0.65–2.45; P=0.48), with specific heterogeneity.
Publication bias and sensitivity analysis
When no significant findings remain unpublished, the 
publication bias may exist, thus artificially inflating the 
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Table 1 Characteristics of included trials







I II III IV
Gaissert (15), 
1996
USA Cohort SL 72 56/16 – 29 31 12 0





SL 29 26/3 60.6±8.7† 9 12 8 0
PN 29 23/6 58.2±9.5† 9 12 8 0
Suen (11), 
1999
USA Cohort SL 58 41/17 63.7‡ 18 28 12 0





SL 60 52/8 60.9±9.5† – – – –
PN 60 53/7 60.6±9.0† – – – –
Martin-Ucar 
(16), 2002
UK Cohort SL 38 27/11 65‡ 10 16 12 0
PN 81 62/18 63‡ 10 32 36 3
Ghiribelli (17), 
2002
Italy Cohort SL 38 36/2 65‡ 16 10 12 0
PN 127 102/25 62.4‡ 29 43 55 0
Deslauriers 
(8), 2004
Canada Cohort SL 184 152/32 60.0±10.0† 82 72 30 0





SL 49 44/5 58.7±7.6† 14 20 15 0
PN 49 46/3 58.1±8.2† 24 13 11 1
Ludwig (19), 
2005
Germany Cohort SL 116 – 62‡ 31 41 44 0
PN 194 – 59‡ 32 52 110 0
Bagan (20), 
2005
France Cohort SL 66 58/8 60.7±8.2† 40 14 12 0
PN 151 138/13 58.2±9.6† 35 35 81 0
Lausberg 
(12), 2000
Germany Cohort SL 104 88/16 62.1±11.4† 22 50 30 2
PN 63 56/7 60.9±11.8† 7 32 21 3
Takeda (21), 
2006
Japan Cohort SL 62 46/16 61.1±10.2† 26 19 17 0
PN 110 92/18 59.3±9.6† 24 14 70 2
Jiménez (22), 
2006
Spain Cohort SL 35 34/1 62‡ – – – –
PN 220 205/5 62‡ – – – –
Balduyck 
(23), 2008
Belgium Cohort SL 10 – 65.3‡ 2 1 7 0
PN 20 – 63.3‡ 3 9 8 0
Melloul (24), 
2008
Switzerland Cohort SL 69 – – – – – –
PN 78 – – – – – –
Parissis (25), 
2009
Ireland Cohort SL 79 54/25 60.4‡ – – – –
PN 129 91/38 62.5‡ – – – –
Hanagiri (26), 
2010
Japan Cohort SL 24 18/6 65.1‡ 5 8 10 1
PN 72 61/11 64.7‡ 5 13 50 4
Table 1 (continued)
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Table 1 (continued)












SL 105 99/6 61.25±8.89† 44 32 26 3
PN 105 98/7 62.24±8.42† 43 36 24 2
Bölükbas 
(28), 2011
Germany Cohort SL 31 25/6 73.6‡ 5 17 8 1
PN 29 25/4 74.2‡ 2 10 15 2
Gómez-Caro 
(29), 2011
Spain Cohort SL 55 51/4 63.5±10.2† 19 27 9 0
PN 21 18/3 62.4±8.2† 3 14 4 0
Lee (30), 
2011
Korea Cohort SL 19 15/4 62.1±8.9† 5 8 6 0





SL 39 28/11 62.1±8.9† 0 6 33 0
PN 39 30/9 64.3±8.8† 0 1 38 0
Cusumano 
(31), 2014
Italy Cohort SL 51 40/11 63.0±8.2† 0 7 44 0
PN 68 54/14 59.7±10.7† 0 3 65 0
Andersson 
(32), 2015
Finland Cohort SL 40 29/11 61.5 8 19 13 0
PN 67 49/18 60 16 26 25 0
Ma (33), 2016 China Cohort SL 58 50/8 58.5±10.3† 0 30 28 0
PN 42 40/2 57.8±7.9† 0 18 40 0
Pagès (34), 
2016
France Cohort SL 941 716/225 60.9±12.6† 190 408 169 32





SL 1,713 959 57.8±15.0† 315 388 118 68
PN 1,713 981 55.4±14.9† 273 419 124 78
†, mean ± standard deviation; ‡, mean. SL, sleeve lobectomy; PN, pneumonectomy; M, male; F, female.
apparent magnitude of an effect. Survival and local recurrence 
rates following SL or PN for the treatment of NSCLC 
were calculated by the fixed-effect model and random-effect 
model, respectively. The two results are similar, and the 
combination of the two results makes them more reliable.
Funnel plots of the study results are shown in Figure 6. 
The funnel plots on 5-year overall survival rates following 
SL or PN for the treatment of NSCLC showed symmetry, 
which suggested there was no publication bias.
Discussion
Sleeve resection for lung cancer can prevent more lung 
parenchyma sacrifice, limiting the physiologic effects of 
PN. Many studies published over the past 20 years show 
similar or better results for parenchymal sparing resections 
compared to PN. Both Deslauriers (8) and Okada (13) 
reported a better prognosis after SL in patients with stages I 
and II NSCLC. Takeda (21) did not show any difference in 
5-year survival for stage I and II patients after SL or PN, but 
the overall 5-year survival in the SL group was better than 
in the PN group (54% vs. 33%). In this meta-analysis 1-, 3-, 
5-year survival rates were 18.26%, 10.95%, 7.34% in the 
PN group and 38.00%, 27.80%, 25.77% in the SL group 
respectively, which is in line with the data of the literature.
From the oncological point of view, each patient 
must have an en-bloc complete resection of the tumor to 
ensure that the margin of resection is negative. Induction 
therapy has shown to improve local and systemic control 
in locally-advanced NSCLC (36-38). However, induction 
therapy may cause fibrosis and treatment-related changes, 
which make dissection of lobar bronchus or artery and 
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reconstructive procedures more complex. Okada (13) 
described that there was a significant difference among 
patient classification of nodal disease N0 or N1 in favor 
of SL. Moreover, Deslauriers (8) reported that among 
patients with N0 disease there was a significant difference 
in favor SL. Mehran and colleagues (39) demonstrated 
a significant difference in survival between N1 and N2 
disease irrespectively to the type of surgical resection 
performed, but they found no difference between N0 and 
N1. Van Schil and colleagues (40) showed there was a 
highly significant difference in survival between patients 
with N0 and N1/N2 disease, even if a similar difference 
in survival was not observed between N1 and N2. Finally, 
both Okada (13) and Deslauriers (8) showed that there was 
no significant difference in survival in N2 disease when 
the type of surgery was taken into account. Mehran and 
Table 2 Summary of the results between SL and PN in the management of NSCLC
Variables No. of studies furnishing data
Results, %
OR (95% CI) P value I2, %
SL PN
Operative mortality 13 (8,10,11,17-19,23-28,30) 2.62 6.30 0.40 (0.25–0.63) <0.0001 0
30-day mortality 12 (14-16,20-22,29,32-36) 2.78 5.86 0.55 (0.32–0.96) 0.04 55
Local recurrence 15 (8,10,13,16,17,19,21,25,27,28,30-34) 15.65 22.81 1.09 (0.72–1.64) 0.69 50
Distant recurrence 9 (10,21,27,28,30-34) 19.81 30.64 0.61 (0.45–0.82) 0.001 0
Complication 15 (10,13,14,16-21,24,28,29,31-33) 29.39 30.58 1.07 (0.87–1.31) 0.55 27
Overall survival
1-year 8 (11,14,15,20,21,28,29,35) 38.00 18.26 1.53 (1.31–1.80) <0.00001 4
3-year 11 (11,13,17,20,21,27-30,32,35) 27.80 10.95 1.78 (1.47–2.17) <0.00001 30
5-year 20 (8,11,13,14,16-22,25-29,32-35) 25.77 7.34 1.96 (1.70–2.27) <0.00001 43
Subgroup overall survival (N0, N1 and N2 patients)
3-year (N2 patients) 3 (13,17,22) 29.78 19.51 1.12 (0.47–2.68) 0.79 35
5-year (N2 patients) 3 (8,13,18) 19.77 18.69 1.27 (0.65–2.45) 0.48 44
5-year (N0 and N1 
patients)
5 (8,13,17,18,22) 57.77 37.29 2.14 (1.66–2.78) <0.00001 13
SL, sleeve lobectomy; PN, pneumonectomy; NSCLC, non-small cell lung cancer; OR, odds ratio; 95% CI, 95% confidence interval.
Figure 2 Distant recurrence rates of SL vs. PN. SL, sleeve lobectomy; PN, pneumonectomy; OR, odds ratio; 95% CI, 95% confidence 
interval.
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colleagues (39) reported that no patients with N2 disease 
survived longer than 5 years after sleeve resection, and 
Okada and colleagues (13) reported a 21% 5-year survival 
rate after sleeve resection in the same subgroup of patients. 
In this meta-analysis, a better 5-year OS was observed after 
SL in case of N0 and N1 patients, but no difference in 3- 
and 5-year OS was observed in case of N2 disease.
Recent reports have shown that an SL can be performed 
with a much lower rate of operative mortality (1.2–7.5%) 
as compared with PN (4.9–12.0%) (8,9,12,19,41). SL was a 
safe procedure with few operative morbidities (10,15,42,43). 
In a meta-analysis, Ferguson and Lehman (9) reported that 
the weighted mean operative mortality was 4.1% after SL 
and 6.0% after PN (P=0.3). Deslauriers and colleagues (8) 
described four times greater operative mortality after PN 
compared to SL (5.3% vs. 1.6%, P=0.036). Recently, SL 
mortality has been reported ranging between 2% (37) and 
5% (44). Also, our results confirm this trend and are in line 
Figure 3 Three-years overall survival rates for SL vs. PN. SL, sleeve lobectomy; PN, pneumonectomy; OR, odds ratio; 95% CI, 95% 
confidence interval.
Figure 4 Five-years overall survival rates for SL vs. PN. SL, sleeve lobectomy; PN, pneumonectomy; OR, odds ratio; 95% CI, 95% 
confidence interval.
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with those of the international literature.
Our study showed that there was no statistically significant 
difference in 30-day mortality. Deslauriers is often quoted 
as saying that “pneumonectomy is a disease”. The main 
causes of death after PN were: circulation complications 
[heart failure (45)], acute respiratory failure, acute respiratory 
distress syndrome (ARDS) (46), arrhythmia and renal disease. 
Compared with SL, PN can cause sudden and significant 
hemodynamic changes, hypoxemia, and mediastinal 
displacement. PN can also predispose to arrhythmia. Right 
ventricular overload and dysfunction can occur as a result 
of pulmonary hypertension and subtle fluid overload is 
often poorly tolerated. Postoperative quality of life has 
been advocated as one of the most reliable indicators that 
should influence the decision to perform an SL rather than 
a PN. Several studies indicate that lung parenchyma sparing 
improves postoperative quality of life because of a greater 
pulmonary reserve. Gómez-Caro (29) and Melloul (24) 
reported there was a statistically significant difference 
favoring SL in terms of postoperative loss of forced 
expiratory volume in 1 second (FEV1).
On the other hand, SL may have a unique set of 
complications in its own right. Anastomotic dehiscence 
may be life-threatening, and often completion PN is 
needed. Anastomotic stenosis and consequent obstructive 
atelectasis are also major complications after SL, while 
postpneumonectomy empyema and respiratory failure 
are the most common complications after PN. Our study 
reports that the rate of postoperative complications was 
29.39% and 30.58% in the SL and PN group, respectively, 
without statistically significant difference.
We may be concerned that bronchoplasty for malignant 
tumors may increase the potential for local recurrence. 
According to Tedder and colleagues (44), the local 
recurrence rate was 13% after SL. Other series reported an 
estimated 20% to 23% rate of local recurrence (39). In this 
study, the weighted 15.6% mean local recurrence rate after 
SL and 22.8% after PN (P=0.69). The significant lower 
recurrence rate after SL (19.81% vs. 30.64% after PN, 
P=0.001) might also explain why the SL group experienced 
a better overall survival. The lower distant recurrence 
rate is an essential explanation in the survival advantage of 
SL, and the survival also may be influenced by the lesser 
physiological insult of SL. Alterations in immune response 
following the physiologic changes with PN have been 
suggested to play a role in distant recurrence (47).
Limitations of the study
The conclusions of our study may be limited by several 
factors. First, the studies analyzed have a very long period. 
This can lead to false positive or false negative results 
(risk of random errors). Second, not all data comes from 
RCTs. Therefore, the overall level of clinical evidence was 
Figure 5 Five-year overall survival-N0 and N1 patients. SL, sleeve lobectomy; PN, pneumonectomy; OR, odds ratio; 95% CI, 95% 
confidence interval.
Figure 6 Funnel plot 5-year overall survival rates. SE, standard 
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relatively low.
There was a concern for publication bias in the studies 
included. Those surgeons with less than optimal experiences 
or outcomes inferior to a thoracotomy would likely be less 
than enthusiastic about publishing their data if they were 
accepted for publication at all. Moreover, there are many 
subtle differences in technique between surgeons. Also, 
funnel plots can show the cause of asymmetry rather than 
publication bias. As a result, our merger may overestimate the 
real effect. Due to these data limitations, our meta-analysis 
was unable to analyze the quality of life score and stratified 
analysis of other possible confounding factors. If the method 
is to be more effective, then larger samples and randomized 
controlled studies with longer follow-up are required.
Finally, we failed to perform a separated analysis 
according to the tumor’s histology because of the very 
limited data available. Darling’s IIIA NSCLC study and 
Deslauriers excellent results indicated that if the surgery is 
performed the surgery it has some clinical impact.
Conclusions
Our study demonstrates improved survival following SL vs. 
PN in patients with NSCLC. This effect was irrespective 
of lymph node involvement when the disease was N0–N1. 
The presence of mediastinal lymph node metastases (N2) 
portended worse survival, that was irrespective of the type 
of surgery. SL is a useful alternative to PN for operable 
cases of lung cancers and should be taken into account. 
Further RCTs are warranted to clarify the exact value of SL 
and PN for NSCLC to get a higher level of evidence.
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